Tuesday, August 08, 2017 4:34:23 PM
http://ir.cocrystalpharma.com/press-releases/detail/37
Recent COCP News
- Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs • GlobeNewswire Inc. • 03/28/2024 12:00:00 PM
- Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A • GlobeNewswire Inc. • 03/19/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 09:15:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:00:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 09:01:43 PM
- Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates • GlobeNewswire Inc. • 01/04/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/02/2024 02:53:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 10:00:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/06/2023 01:00:40 PM
- Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A • GlobeNewswire Inc. • 12/06/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 01:00:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/29/2023 01:00:21 PM
- Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast • GlobeNewswire Inc. • 11/29/2023 01:00:00 PM
- Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023 • GlobeNewswire Inc. • 11/27/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 01:15:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 01:01:00 PM
- Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs • GlobeNewswire Inc. • 11/13/2023 01:00:00 PM
- Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast • GlobeNewswire Inc. • 11/09/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2023 12:00:18 PM
- Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344 • GlobeNewswire Inc. • 10/31/2023 12:00:00 PM
- Cocrystal Pharma Doses First Subjects in Clinical Study of CDI-988 For Pandemic Norovirus and Coronavirus • GlobeNewswire Inc. • 09/28/2023 12:00:00 PM
- Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference • GlobeNewswire Inc. • 09/05/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2023 08:05:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 12:00:50 PM
- Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs • GlobeNewswire Inc. • 08/14/2023 12:00:00 PM
FEATURED Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • Apr 22, 2024 8:49 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Kona Gold Beverages, Inc. Prepares for First Production Run Set to Launch May 17, 2024 • KGKG • Apr 22, 2024 8:30 AM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM